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The invasive disease from Neisseria meningitidis is one of the lead-
ing causes of death for meningitis and sepsis at all ages. The highest 
incidence of cases occurs at paediatric and adolescent age, but no 
age of life is considered protected from this infection and disease.
Prevention against the five main serogroups is possible using the 
combined conjugated polysaccharide vaccine against the ACWY 
(anti-MenACWY) serogroups and the meningococcal B (anti-
MenB) protein vaccines. 
Trumenba® vaccine, approved by the EMA (European Medicine 
Agency) for use in individuals aged ≥ 10 years, protects against 
serogroup B invasive disease.
This bivalent, recombinant vaccine is able, when given with a 0-6 
month schedule, to induce a protective response in adolescents 
and young adults, comparable with a 3-doses schedule.
For this reason, the Trumenba® vaccine should be used routinely 
with the 2-dose schedule (0-6 months). The 3-doses use could be 
considered in particular situations, like an occurring epidemic or 
particular individual risk factors such as asplenia or complement 
deficit, but is not needed for underlying conditions like diabetes 
or heart diseases.
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Introduction
The invasive disease from Neisseria meningitidis is one 
of the leading causes of death for meningitis and sepsis 
at all ages [1]. The highest incidence of cases occurs at 
paediatric and adolescent age, but no age of life is con-
sidered protected from infection and disease. There are 
five Neisseria meningitidis serogroups most frequently 
involved in invasive infections: A, B, C, W, Y  [2, 3]. 
There is now the possibility of prevention against the 
five serogroups using the combined conjugated polysac-
charide vaccine against the ACWY (anti MenACWY) 
serogroups and the meningococcal B (anti-MenB) pro-
tein vaccines. 
The use of anti-meningococcal C and tetravalent anti 
ACWY vaccines is well established; data regarding 
safety, protective efficacy and administration protocols 
to be used are well known. 
Prophylaxis against meningococcus B can be performed 
with two vaccines, the Bexsero® vaccine, marketed in 
Italy by GlaxoSmithKline and indicated for use both in 
childhood and adolescence and in adulthood, and the 
Trumenba® vaccine, marketed in Italy by Pfizer and 
registered for use in adolescents and adults. Both are 
protein vaccines. The proteins inserted in the vaccines 
are produced with recombinant DNA technologies. The 
Bexsero® vaccine is used with a 2-dose protocol in chil-
dren > 2 years and adolescents; the Trumenba® vaccine, 
recently introduced in use in Italy, has a 2- or 3-dose 
posology [4, 5]. This has raised some issues in health-
care workers regarding the calendar to be used with this 
vaccine. 
Moreover, since the University of Florence is conduct-
ing a Health Technology Assessment (HTA) study to 
support health policy makers in the use of Trumenba® 
within vaccine policies funded by the Servizio Sanitar-
io Nazionale (National Health Service), it is crucial, to 
establish the conditions where the use of the two-dose 
schedule is indicated and, on the other hand, when three 
doses are advised. The aim of this work is therefore to 
provide the most recent scientific evidence that can sup-
port the use of one schedule or the other, and facilitate 
the HTA evaluation of the product. 
Trumenba® vaccine in adolescents: 
immunogenicity studies and bactericidal 
activity. 
The bivalent, recombinant Trumenba® vaccine contains 
two variants of factor H-binding protein (fHBP) and has 
been approved by the EMA (European Medicine Agen-
cy) for use in individuals aged ≥ 10 years [5]. Like in the 
past for meningococcal polysaccharide vaccines, also 
for meningococcal B protein vaccines, it was not pos-
sible to carry out clinical efficacy studies due to the low 
incidence of invasive meningococcal disease. Instead, 
several immunogenicity studies have been performed: 
antibody production and bactericidal activity have been 
considered as a correlate of protection. 
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The fHbp protein is present on virtually all meningo-
cocci; however, for antibodies induced by the vaccine 
to guarantee bactericidal activity, the amount of fHbp 
present on the surface of the meningococcus needs to be 
sufficiently high as to be recognised by the antibodies. 
In this regard, the studies that analysed the amount of 
fHbp present on the meningococcal surface have been 
able to demonstrate, on more than 2,150 meningococcus 
strains, that over 90% of the isolates present a sufficient 
amount of fHbp to trigger the antigen-antibody reac-
tion, and therefore the bactericidal activity of vaccine-
induced antibodies [5, 6]. 
The peculiarity of the studies of bactericidal activity of 
the Trumenba® vaccine is that they were performed by 
testing the vaccine-induced antibody production against 
heterologous strains (i. e. strains that exhibit antigens 
other than those contained in the vaccine) of meningo-
cocci, expressing different sub-variants of fHbp, and a 
different amount of protein on the surface of the menin-
gococcus. Another peculiarity is that the vaccine anti-
gens of Trumenba® (A05 and B01) are derived from both 
existing subfamilies of fHbp (A and B) with the aim of 
including the set of circulating forms of meningococ-
cus B (subfamily A comprises about 30% of circulating 
forms, whilst subfamily B comprises about 70%). 
In detail, fHbp proteins are different from meningococ-
cus to meningococcus: there are numerous forms that can 
be grouped in the two indicated subfamilies (in detail, 
subfamily A and B according to the Pfizer classification, 
or variants 1, 2, 3 according to the Novartis classifica-
tion (Oxford classification), with Pfizer’s subfamily A 
corresponding to the Oxford variants two and three, and 
Pfizer’s subfamily B corresponding to the Oxford vari-
ant 1 [7]. Within these subfamilies, there are many (over 
200) fHbp sub-variants. For this reason, it is very impor-
tant to be sure that the antibodies produced by the vac-
cine are effective against most of these sub-variants (i. e. 
directed against both subfamilies) and therefore against 
different meningococcus strains. Today we know that 
not all the sub-variants are equally frequent and that in 
80% of meningococcus strains, the same 10 sub-variants 
are present [8]. 
Regarding the bactericidal activity against different 
sub-variants, studies have been conducted towards the 
main sub-variants A22, A56, B24 and B44, detected 
by current epidemiological investigation (actual inva-
sive MenB disease strains from reference laboratories 
in Europe and the United States) and belonging to both 
meningococcus subfamilies A and B. These aspects 
characterise the development of the vaccine. The studies 
were then further extended to other 10 sub-variants also 
circulating in Europe and the USA, for a total of 14 sub-
variants expressed by current epidemiology [9]. Despite 
the antibody titre needed to induce protection (correlate 
of protection) being a hSBA 1:4 titre, in the Trumenba® 
development studies a higher dilution titre was used as 
a protection correlate (1:8 for A56, B24 and B44 and 
1:16 for A22) to strengthen the certainty of achieving a 
sufficient antibody titre, using a higher threshold value. 
A 4-fold increase in the seroconversion index was also 
evaluated. These studies were conducted with different 
protocols, including two or three doses [5]. 
Trumenba® vaccine in adolescents: 2 or 3 
doses?
The Vesikari study, conducted in Finland on adolescents 
and young adults, assessed the percentage of subjects 
who achieved or exceeded the antibody titre of bacte-
ricidal activity (hSBA) of 1:8 (i. e. with double dilu-
tion compared to the protection correlate 1:4). With the 
2-dose protocol (0-6 months), the subjects who achieved 
this titre were respectively > 90% against the A22 vari-
ant, > 98% against the A56 variant, > 69% against the 
B24 variant and > 70% against the B44 variant [10]. 
The data therefore confirmed the ability of antibodies 
induced by the vaccine to induce a sufficiently protec-
tive response against meningococci expressing different 
variants of fHbp (i. e. heterologous to the vaccine). The 
data of the study allowed to conclude that the Trumenba® 
vaccine is able, when given with a 0-6 month calendar, 
to induce a protective response in adolescents and young 
adults comparable with a 3-dose schedule. The authors 
also conclude that increasing the time between the two 
doses improves the induced antibody response so much 
that protocol 0-6 month is preferable to protocol 0-4 or 
0-2 or 0-1 month. 
The results of the study were therefore that both the 
2- and 3-dose calendars induce a robust immune re-
sponse [10]. 
Precisely for this reason, the Trumenba® vaccine should 
be used routinely with the 2-dose schedule (0-6 months). 
The 3-dose use could be considered in particular situ-
ations, when it is necessary, for example in travellers 
heading to endemic areas, to be protected in a short time 
because of an outbreak occurrence; in that case, a sched-
ule 0-1 month (before departure) can be used, followed 
by a third dose at month 6. 
For example, this was indicated in the recommendations 
of the Advisory Committee on Immunization Practices 
Fig. 1. Phylogenetic tree of meningococcal fHbp proteins (Don-
ald et al., mod. [8]).
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(ACIP) updated as of May 2017, which show that, in 
routine conditions, two doses are recommended in sub-
jects not exposed to risk. It is important to remember that 
“patient at increased risk” does not mean a patient with 
an underlying disease (e. g. diabetes, heart disease, etc.). 
The first 2015 ACIP recommendations indicate precisely 
the conditions of increased risk and specifically: “Per-
sons with persistent complement component deficiencies, 
persons with anatomic or functional asplenia, microbi-
ologists routinely exposed to isolates of Neisseria men-
ingitides, persons identified as at increased risk because 
of a serogroup B meningococcal disease outbreak. ” The 
recommendations mentioned above also indicate that if 
the interval between the two doses is equal to or greater 
than 6 months, the third dose in those at risk is no longer 
necessary, demonstrating a 3-dose rationale linked solely 
to the need to accelerate the schedule [11, 12]. 
Adding further doses to vaccination calendars often 
causes a reduction in adherence to the prescribed num-
ber of administrations in patients and families, and this 
is especially true in adolescents, who are in any case dif-
ficult to reach. US data obtained on a typical adolescent 
vaccination, the anti HPV, have shown that vaccination 
coverage decreases with doses following the first: 60% 
for the first dose, 50. 3% for second and 39. 7% for the 
third dose [13]. A similar decreasing trend is also present 
in Italy. 
The data obtained in the Vesikari [10] study were evalu-
ated and analysed in further publications with the con-
clusion that a two-dose schedule (0-6 months) is per-
fectly usable in vaccination practice [14, 15]. 
Given the very rapid evolution of the clinical conditions 
characteristic of the disease (which may evolve towards a 
very serious or even fatal situation in less than 24 hours), 
it appears appropriate to provide a periodic booster dose 
for all subjects at risk for age or other conditions (work, 
travel) in order to take advantage of the immunological 
memory induced by vaccination. This procedure is ap-
propriate also for vaccination against meningococcus B, 
just as for vaccinations against meningococcal vaccines 
C or ACWY [5, 15]. The timing recommended for car-
rying out this booster vaccine should be established in 
the future by monitoring the antibody kinetics in popu-
lations of vaccinated subjects followed in the years after 
the basic immunisation course. 
Conclusions
Trumenba® vaccine is able, when given with a 0-6 month 
schedule, to induce a protective response in adolescents 
and young adults, comparable with a 3-doses sched-
ule. For this reason, the Trumenba® vaccine should be 
used routinely with the 2-dose schedule (0-6 months). 
The 3-doses use could be considered in particular situ-
ations. These are clearly addressed in the recommenda-
tions of the Advisory Committee on Immunization Prac-
tices (ACIP) updated as of May 2017: three doses are 
recommended in subjects at increased risk, not mean-
ing patients with an underlying disease (e. g. diabetes, 
heart disease, etc. ) but, as the first 2015 ACIP recom-
mendations precisely indicate: “Persons with persistent 
complement component deficiencies, persons with ana-
tomic or functional asplenia, microbiologists routinely 
exposed to isolates of Neisseria meningitides, persons 
identified as at increased risk because of a serogroup B 
meningococcal disease outbreak. ”
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